Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AGBA - The Share Split will entitle each shareholder of the Company’s ordinary shares (“AGBA Ordinary Shares”) as of the Record Date to receive 1.9365 AGBA Ordinary Share for each one AGBA Ordinary Share owned.
https://www.otcmarkets.com/filing/html?id=17870688&guid=RdL-kHvy7FA_B3h
$LBRG Ladybug Surpasses $6 Million in Revenue for First Half of Year
https://www.globenewswire.com/en/news-release/2024/10/02/2956923/0/en/Ladybug-Surpasses-6-Million-in-Revenue-for-First-Half-of-Year.html
$SRMX Tri Cascade Inc. Unveils TRITOM GX500G IoT 5G Modem at Mobile World Congress Las Vegas
*Groundbreaking low-latency modem delivers fast, reliable, and secure 5G connectivity
for industrial, remote and mobile applications
https://www.otcmarkets.com/otcapi/company/dns/news/document/77475/content
$AGBA - This development marks another important milestone as the merger of AGBA and Triller enters its final phase of completion. It also further cements the strategic relationship between AGBA and Yorkville, a leading global investment fund providing growth and acquisition capital to public companies
https://finance.yahoo.com/news/agba-group-one-nasdaq-top-130000537.html
$RFHRF Renforth Resources Inc. Reports Success on Initial Sorting Test of Victoria Polymetallic Mineralization
https://www.thenewswire.com/press-releases/1k1vFKO8o-renforth-resources-inc-reports-success-on-initial-sorting-test-of-victoria-polymetallic-mineralization.html
We're excited to share that 1606 Corp. (OTC: $CBDW) was recently featured in an article highlighting promising companies making waves in various industries. Our strategic move into AI-powered healthcare through a partnership with Adnexus positions us at the forefront of innovation, particularly in treatments for infectious diseases like HIV and SARS-CoV-2. With the global AI market projected to surpass $2.25 trillion by 2030, 1606 Corp. is poised for significant growth in the AI-driven healthcare sector.
https://lnkd.in/gJmhJEBd
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression
Ketamine is currently used off-label for this indication. However, FDA approval is typically required for patients to obtain insurance reimbursement
NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use
RADNOR, Pa., Sept. 30, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today announced that twelve-month real-time stability on the first manufactured lot of NRX-100 (Ketamine) at Nephron Pharmaceuticals, utilizing commercial scale processes, was reached on September 24, 2024. In this process, no degradation of the active ingredient was observed. These findings are consistent with projected room temperature shelf stability in excess of three years. Accelerated stability on additional manufactured lots of preservative-free product is congruent with stability seen in this initial lot.
Demonstrating the ability to manufacture drug product, and prove its stability, are critical components of the drug approval process with the US FDA. Filing of the NDA for NRX-100 is on track for 2024. The NRX-100 formulation is the first sterile, single dose vial prepared with without the addition of preservatives, which may have toxic effects with repeated use.
"We are pleased to reach this important milestone in our preparation of the NDA for NRX-100, a drug we believe can significantly benefit the 3.8 million people who make a plan to commit suicide in the United States each year1," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "I would like to congratulate the manufacturing team from our partner Nephron Pharmaceuticals for helping us take this important step forward in bringing hope to life."
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 inpatients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
_________________________
1 https://www.cdc.gov/suicide/facts/data.html
https://c212.net/c/img/favicon.png?sn=CL18716&sd=2024-09-30 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-completion-of-twelve-months-of-stability-on-the-first-manufactured-commercial-scale-lot-of-nrx-100-ketamine-302262032.html
SOURCE NRx Pharmaceuticals, Inc.
HEALTHCARE BREAKOUT STOCK-AMAZING 🤩 CHART— https://www.barchart.com/stocks/quotes/ICBU/opinion
3 MILLION SHARES x .034=$102,000-WOW-BREAKOUT- https://www.stocktitan.net/news/ICBU/i-md-companies-inc-completes-acquisition-of-riize-ulbrsk3t40pj.html
HEALTHCARE ACQUISITION -https://www.tipranks.com/news/press-releases/imd-companies-inc-subsidiary-riize-llc-to-expand-product-line-with-contracted-telemedicine-doctors
TICKER $ICBU
3 MILLION SHARES x .034=$102,000-WOW-BREAKOUT
AMAZING 🤩 CHART— https://www.barchart.com/stocks/quotes/ICBU/opinion
$AGBA $4 Billion Mega Merger Between #AGBA Group Holding Limited and #Triller Corp. Shareholders of AGBA Recently Approved the Merger.
https://soundcloud.com/smallcapstockstoday/info-on-pending-mega-merger-with-agba-and-triller
$LAZR News out today - Comprehensive analysis of Luminar - Details of the recently proposed trade restrictions, competition, potential catalysts, growth drivers, financials, key customers, and more >>> https://nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-luminar-technologies-and-proposed
$BULT Quarterly Report
https://www.otcmarkets.com/otcapi/company/financial-report/413272/content
$XXII stands out as a trailblazer with its innovative approach to smoking alternatives. https://allcapresearch.com/f/22nd-century-group-inc-pioneering-a-new-era-in-tobacco-products
$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company https://finance.yahoo.com/news/1606-corp-signs-letter-intent-120000809.html
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$XXII Great level to load!
$XXII updated chart, getting real close to breaking this descending wedge! Would be hugely #bullish. https://t.co/6GxN3pqCqG pic.twitter.com/xjUcvyAV99
— Screech (@MrSamuelPowers) September 24, 2024
$RJDG RJD Green Inc. (OTCPK: RJDG) announced Silex Holdings Inc. has acquired the assets of JSI Interiors to include the state-of-the-art fabrication system, contracts, purchase orders, and book of business. The combined revenues of the companies for calendar year 2023 was $7,813,426.
https://finance.yahoo.com/news/rjd-green-inc-silex-holdings-130000684.html
$INTV Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.
https://finance.yahoo.com/news/integrated-ventures-inc-announces-strategic-124500730.html
$CBDW BIG NEWS!!! EXCITING WEBINAR PLANNED FOR OCTOBER 10TH!!
$CBDW @CBDWinc Exciting Webinar planned for October 10th with CEO Austen Lambrecht! Check out https://t.co/Om8NlDIlw1 for more information. $BBIG $ALLR $NSAV $PSIG $HOLO $ENZC $BGBG $VINCI $MATIC $NHMD $SERV @MrSamuelPowers @DACE0325 pic.twitter.com/I6Xbw7cF1h
— 🔥🔥🌐UltimateTraderX🌐🔥🔥 (@JediJazz22) September 19, 2024
$XONI Xtreme Fighting Championships Announces Innovative NIL Partnership with World-Class College Wrestlers and Combat-Sport Veterans
https://www.globenewswire.com/en/news-release/2024/09/19/2949254/0/en/Xtreme-Fighting-Championships-Announces-Innovative-NIL-Partnership-with-World-Class-College-Wrestlers-and-Combat-Sport-Veterans.html
$CBDW 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606") is pleased to announce it has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research.
https://www.accesswire.com/918717/adnexus-biotechnologies-partners-with-1606-corp-for-strategic-investment-to-revolutionize-ai-driven-drug-discovery
$DDDX 3D Printing stocks Featured
https://richardacavalli.wixsite.com/greenplanetmicrocaps/3d-printing-to-explode
$UNCY today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY.
https://finance.yahoo.com/news/unicycive-therapeutics-present-virtual-life-110300237.html
$DYAI Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbumin
https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html
$LPTH announced the global launch of a new version of the Mantis™ camera, specifically designed for monitoring high-temperature processes inside boilers and furnaces in power plants, and first commercial order for furnace inspection at a customer in southeastern US. https://finance.yahoo.com/news/lightpath-launches-next-gen-mantis-123000011.html
$AIMD is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). https://finance.yahoo.com/news/ainos-secures-taiwan-invention-patent-123000316.html
$CBDW GET IN EARLY!! HEARING HUGE NEWS/UPDATE COMING VERY SOON...
$UNCY announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY. https://finance.yahoo.com/news/unicycive-therapeutics-present-virtual-life-110300237.html
The Strategic Partnership with 1606 Corp $CBDW https://allcapresearch.com/f/the-ai-platform-a-game-changer-in-biotechnology
$RJDG RJD Green Inc.’s Silex Holdings Division Announces Mark Gould as the Tulsa, Oklahoma Division Manager
https://www.globenewswire.com/en/news-release/2024/09/11/2944568/0/en/RJD-Green-Inc-s-Silex-Holdings-Division-Announces-Mark-Gould-as-the-Tulsa-Oklahoma-Division-Manager.html
$SSII SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline
https://www.globenewswire.com/en/news-release/2024/09/11/2944469/0/en/SS-Innovations-Conducts-Interactive-Meeting-with-the-Center-for-Devices-and-Radiological-Health-CDRH-of-the-Food-and-Drug-Administration-FDA-and-Updates-its-Expected-FDA-Approval-T.html
$RFR Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Releases Status Report in Sector Noted as ‘Essential Contributor’
https://www.miningnewswire.com/renforth-resources-inc-cse-rfr-otcqb-rfhrf-releases-status-report-in-sector-noted-as-essential-contributor/
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
MIAMI, Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024.
The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.
Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will provide an overview of the Company's business during the presentation.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.
Access to the presentation can also be found at https://ir.nrxpharma.com/events beginning at 7:00AM ET Monday September 9, 2024.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About H.C. Wainwright & Co.
H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL96063&sd=2024-09-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-announce-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-september-9-11-2024-302236168.html
SOURCE NRx Pharmaceuticals, Inc.
$VINO Gaucho Holdings Announces Collaboration with Renowned Argentine Artist Aldo Sessa
https://finance.yahoo.com/news/gaucho-holdings-announces-collaboration-renowned-143000334.html
$UNCY Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis https://finance.yahoo.com/news/unicycive-therapeutics-announces-submission-drug-110300693.html
$LPTH LightPath Technologies Achieves Key Qualification Milestone With Lockheed Martin for US Army Missile Program https://finance.yahoo.com/news/lightpath-technologies-achieves-key-qualification-123000761.html
$DYAI Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html
Why Now is the Time to Invest in AI Technology $CBDW https://cbdw.ai/why-now-is-the-time-to-invest-in-ai-technology/
$BTTC Bitech Technologies Signs Term Sheet of $80 Million Investment Tax Credit for Its Flagship BESS Project
https://finance.yahoo.com/news/bitech-technologies-signs-term-sheet-113000785.html
$INTV Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market
https://www.prnewswire.com/news-releases/integrated-ventures-acquires-51-stake-in-gettrimcom-tm-telemedicine-platform-with-focus-on-expansion-into-booming-glp-1-powered-weight-loss-market-302238064.html
$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
https://finance.yahoo.com/news/1606-corp-signs-letter-intent-120000809.html
$RITE Company Tweet
Mineralrite Corporation
@Mineralrite
CRDNews is now emailing the follow-up message in the $RITE Exposure Campaign which started in July. This message can be seen at: https://crdnews.info/RITE_2024-08-27.html
the prior at: https://crdnews.info/RITE_2024-07-17.html #MineralRite #RITE #InvestorRelations #OTCMarkets
https://x.com/Mineralrite
$CBDW CBDW AI Chatbot: Leading the Way in Investor Relations https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview
$AMPG News: AmpliTech Group’s AGMDC Division Moves to Allen Tech Hub in Watters Creek District In Allen Texas
https://finance.yahoo.com/news/amplitech-group-agmdc-division-moves-133000969.html
$VINO Gaucho Holdings Announces Collaboration with Renowned Argentine Artist Aldo Sessa
https://finance.yahoo.com/news/gaucho-holdings-announces-collaboration-renowned-143000334.html
$AIMD Company invites shareholders and all interested parties to learn our journey for ultimately becoming AI's nose capable of digitizing smell. https://finance.yahoo.com/news/ainos-participate-h-c-wainwright-123000697.html
$DYAI Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html
$CBDW 1606 Corp CEO with Key Highlights from Recent Redchip Interview https://allcapresearch.com/penny-stocks/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview
$GNPX: Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes
Video Highlights Recent Oncology Clinical Development Program Updates
AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.
The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."
Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."
On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.
We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."
To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html
SOURCE Genprex, Inc.
$HALB Halberd Corp. - Taking a Moment to Recenter Our Technical Progress
Introducing Tri-axTM TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal
https://www.globenewswire.com/en/news-release/2024/08/26/2935424/0/en/Halberd-Corp-Issues-Letter-to-Shareholders.html
$BHAT News August 15, 2024
Blue Hat Expands into Gold Trading with Strategic Partnerships As Gold Prices Rise Amid Economic Optimism
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |